Navigation Links
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Date:8/24/2014

as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation alirocumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials, such as the ODYSSEY global trial program evaluating alirocumab; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, including without limitation alirocumab; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products an
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron Announces Upcoming 2014 Investor Conference Presentations
2. Regeneron Reports Second Quarter 2014 Financial and Operating Results
3. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
4. Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration
5. Regeneron Announces Upcoming 2013 Investor Conference Presentation
6. Sanofi and Regenerons Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
7. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
8. Regeneron Reports Third Quarter 2013 Financial and Operating Results
9. Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
10. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
11. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
(Date:9/17/2014)... Sutro Biopharma, a biopharmaceutical company developing antibody ... of Merck KGaA, Darmstadt, Germany , ... United States and Canada ... develop antibody drug conjugates (ADCs). ADCs are composed of ... is thought to specifically target and deliver the cytotoxic ...
(Date:9/17/2014)... , Sept. 17, 2014  Fortune Oil and Gas, ... its name to Manzo Pharmaceuticals, Inc. with the symbol ... effect today, September 17, 2014. Also taking effect today ... The approval is a pivotal event in the company,s ... Manzo explained, "We could not proceed with the plan ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3
(Date:9/17/2014)... In its latest blog post, Best Drug Rehabilitation , ... by during a stay in rehab can make a big ... highlighting a member of the therapeutic care team that is ... the country and around the world: dogs. , ... heart rate, and stress levels in recovering addicts,” commented Best ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
(Date:9/17/2014)... 17, 2014Scientists at The Scripps Research Institute (TSRI) ... that is powerfully effective against vancomycin-resistant strains of ... vancomycin analog appears to have not one but ... bacteria probably cannot evolve resistance quickly. , "This ... will still be in clinical use a generation ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... HealthDay Reporter , TUESDAY, Oct. 26 (HealthDay News) ... could be prevented if people followed five simple healthy ... which would improve overall health as well -- include ... maintaining a healthy weight, the researchers say. "Even ...
... respond to hormonal changes and inflammation has been awarded ... five-year study. The research programme at the National ... is led by Professor Julian Davis, a consultant endocrinologist ... of Manchester,s Developmental Biomedicine Research Group. He is ...
... Professor Zhipeng Wu has invented a portable scanner based on radio ... presence of tumours malignant and benign in the breast ... breast cancer detection has been proven by researchers in the US, ... few minutes for an image to be produced, and this had ...
... is not considered effective treatment for KRAS (a gene)-mutated ... colorectal cancer not responding to chemotherapy and a certain ... had longer overall and progression-free survival than patients with ... 27 issue of JAMA . "Recent ...
... TUESDAY, Oct. 26 (HealthDay News) -- Children who survive ... on, a new study suggests. The findings highlight ... among childhood cancer survivors, the researchers said. "Current ... cancer, but we know that many cancer therapies -- ...
... 26 (HealthDay News) -- Primary care doctors earn the ... one reason for U.S. medical students, declining interest in ... at the wages of 6,381 physicians providing patient care ... primary care; surgery; internal medicine and pediatric subspecialties; and ...
Cached Medicine News:Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Portable breast scanner allows cancer detection in the blink of an eye 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Childhood Cancer Survivors Risk Future GI Problems 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: